Dimensional Fund Advisors LP boosted its stake in Bausch + Lomb Co. (NYSE:BLCO - Free Report) by 66.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 109,619 shares of the company's stock after purchasing an additional 43,740 shares during the quarter. Dimensional Fund Advisors LP's holdings in Bausch + Lomb were worth $1,979,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also bought and sold shares of the stock. Blue Trust Inc. increased its holdings in shares of Bausch + Lomb by 68.3% in the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock worth $48,000 after buying an additional 1,004 shares during the last quarter. FNY Investment Advisers LLC bought a new position in Bausch + Lomb in the fourth quarter valued at $72,000. Commonwealth Equity Services LLC purchased a new stake in Bausch + Lomb during the fourth quarter valued at about $181,000. Covestor Ltd purchased a new stake in Bausch + Lomb during the fourth quarter valued at about $188,000. Finally, Orion Portfolio Solutions LLC bought a new stake in Bausch + Lomb during the fourth quarter worth about $225,000. 11.07% of the stock is currently owned by institutional investors.
Bausch + Lomb Stock Performance
Shares of NYSE:BLCO opened at $11.37 on Thursday. The company has a current ratio of 1.60, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72. The company has a 50-day moving average price of $13.19 and a 200-day moving average price of $16.41. The company has a market cap of $4.02 billion, a price-to-earnings ratio of -12.49, a price-to-earnings-growth ratio of 0.85 and a beta of 0.58. Bausch + Lomb Co. has a 12 month low of $10.45 and a 12 month high of $21.69.
Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.10). Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The business had revenue of $1.15 billion for the quarter, compared to the consensus estimate of $1.15 billion. During the same period in the previous year, the company earned $0.07 EPS. The company's revenue for the quarter was up 3.5% on a year-over-year basis. As a group, equities analysts anticipate that Bausch + Lomb Co. will post 0.74 EPS for the current year.
Analysts Set New Price Targets
BLCO has been the subject of several research reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Bausch + Lomb in a research note on Thursday, April 24th. Evercore ISI lowered their price objective on shares of Bausch + Lomb from $19.00 to $15.50 and set an "outperform" rating for the company in a report on Thursday, May 1st. Royal Bank of Canada reduced their target price on shares of Bausch + Lomb from $18.00 to $17.00 and set an "outperform" rating on the stock in a report on Friday, April 4th. Citigroup lowered their price target on shares of Bausch + Lomb from $14.00 to $13.00 and set a "neutral" rating for the company in a research note on Thursday, May 1st. Finally, Morgan Stanley cut their price target on shares of Bausch + Lomb from $18.00 to $12.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $15.50.
Check Out Our Latest Stock Analysis on BLCO
About Bausch + Lomb
(
Free Report)
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bausch + Lomb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch + Lomb wasn't on the list.
While Bausch + Lomb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
